Luspatercept - Latest Advances

Advances in Supportive Therapy for Patients With Thalassemia: A Systematic Review.

Journal: Biological research for nursing

Published: December 07, 2025

Updates in low/intermediate-risk MDS.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Thalassemia and hypercoagulability.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Management of MDS according to risk classifications

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: October 01, 2025

The 511th case: severe anemia with increased ringed sideroblasts

Journal: Zhonghua nei ke za zhi

Published: September 04, 2025

Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review.

Journal: Journal of medical economics

Published: September 02, 2025

Luspatercept combined with roxadustat in the treatment of refractory myelodysplastic neoplasms with ring sideroblasts: a prospective, randomized, single-center study

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: August 31, 2025

Treatment for VEXAS syndrome with luspatercept combined with cyclosporine A, methylprednisolone, and thalidomide: a case report

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: August 31, 2025

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.

Journal: Current hematologic malignancy reports

Published: August 25, 2025

Novel treatment strategies for lower-risk myelodysplastic neoplasms

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 06, 2025

Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents.

Journal: JCO oncology practice

Published: August 05, 2025

Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial.

Journal: British journal of haematology

Published: August 04, 2025

Filters

Advances in Supportive Therapy for Patients With Thalassemia: A Systematic Review.

Advances in Supportive Therapy for Patients With Thalassemia: A Systematic Review.

Updates in low/intermediate-risk MDS.

Updates in low/intermediate-risk MDS.

Thalassemia and hypercoagulability.

Thalassemia and hypercoagulability.

Management of MDS according to risk classifications

Management of MDS according to risk classifications

The 511th case: severe anemia with increased ringed sideroblasts

The 511th case: severe anemia with increased ringed sideroblasts

Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review.

Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review.

Luspatercept combined with roxadustat in the treatment of refractory myelodysplastic neoplasms with ring sideroblasts: a prospective, randomized, single-center study

Luspatercept combined with roxadustat in the treatment of refractory myelodysplastic neoplasms with ring sideroblasts: a prospective, randomized, single-center study

Treatment for VEXAS syndrome with luspatercept combined with cyclosporine A, methylprednisolone, and thalidomide: a case report

Treatment for VEXAS syndrome with luspatercept combined with cyclosporine A, methylprednisolone, and thalidomide: a case report

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.

Novel treatment strategies for lower-risk myelodysplastic neoplasms

Novel treatment strategies for lower-risk myelodysplastic neoplasms

Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents.

Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents.

Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial.

Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial.